AIM:NYE-AIM ImmunoTech Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 2.15

Change

+0.03 (+1.42)%

Market Cap

USD 0.08B

Volume

0.53M

Average Target Price

USD 4.88 (+126.74%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida. Address: 2117 SW Highway 484, Ocala, FL, United States, 34473

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-0.79 (-1.13%)

USD160.71B 24.70 2.74
ADPT Adaptive Biotechnologies Corpo..

+0.59 (+1.23%)

USD6.52B 39.50 N/A
BHVN Biohaven Pharmaceutical Holdin..

+1.85 (+2.93%)

USD3.76B N/A N/A
ADCT ADC Therapeutics SA

+0.12 (+0.37%)

USD2.33B -99,999.99 N/A
ZYME Zymeworks Inc

+1.50 (+3.33%)

USD2.08B 300.20 N/A
MYOV Myovant Sciences Ltd

-1.60 (-10.22%)

USD1.43B N/A N/A
RCUS Arcus Biosciences, Inc

-0.27 (-1.55%)

USD1.13B N/A N/A
KDMN Kadmon Holdings, Inc

+0.18 (+4.67%)

USD0.64B 2.20 N/A
CVM CEL-SCI Corporation

+0.43 (+3.49%)

USD0.48B N/A N/A
PFNX Pfenex Inc

-0.01 (-0.08%)

USD0.44B 268.67 63.90

ETFs Containing AIM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 360.78% 97% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 360.78% 97% A+ 99% A+
Trailing 12 Months  
Capital Gain 241.27% 93% A 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 241.27% 93% A 99% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.01% N/A N/A 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.01% N/A N/A 30% F
Risk Return Profile  
Volatility (Standard Deviation) 1.15% N/A N/A 97% A+
Risk Adjusted Return 0.97% N/A N/A 30% F
Market Capitalization 0.08B 34% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.82 58% F 95% A
Price/Book Ratio 1.74 93% A 40% F
Price / Cash Flow Ratio -9.36 63% D 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -42.21% 70% C- 10% F
Return on Invested Capital -68.81% 58% F 2% F
Return on Assets -25.15% 61% D- 2% F
Debt to Equity Ratio 30.29% 25% F 73% C
Technical Ratios  
Short Ratio 0.64 88% B+ 75% C
Short Percent 4.89% 52% F 49% F
Beta -0.99 96% A 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.